New book by Larry Connors Click here Improve your trading - See how
A dedicated Chat Room for Traxxec has been created at STOCKWIRE.com to discuss this news event.
Visit the following link to begin chatting with your fellow shareholders: http://www.stockwire.com/chat
----------------------------------------------------------
BOCA RATON, FL -- Stem Cell Assurance, Traxxec Inc. (OTC:TRXX) today updated shareholders with regard to the new Board and Officers.
Dr. Vikki Hufnagel has a long and distinguished scientific research history and has contributed to many significant breakthroughs in Patient's Rights, and Women's Rights, in Health Care and Public Law. Dr. Hufnagel has the honor of being the first physician in the United States to co-author state laws to provide informed consent to patients. She has also worked with members of Congress on "Patient Rights" as a Constitutional issue. Dr. Hufnagel has lectured widely and has authored such best-selling books as '"No More Hysterectomies", and articles that present complex scientific material in an easy-to-understand manner for the everyday reader. Her medical expertise, visionary outlook, and compassion have led her to be on many national television programs, such as Oprah, as an expert guest in the field of Medicine.
During her undergraduate work at the University of California Berkeley Dr. Hufnagel realized the life changing benefits of genetic and cellular research taking place, and the possible future medical breakthroughs that might arise from such research. As a student at the University of California San Francisco School of Medicine she worked with the Pediatrics Endocrine group that developed Human Growth Hormone for the treatment of short stature, later that team formed Genentech. She went on to be named a National Institutes of Health Fellow in Reproductive Genetics under Dr. Mitchell Golbus at University of California San Francisco during the early years of in utero fetal diagnosis and treatment. In the lab, her research focused on cellular genetic and biochemical determinations. During her years at Cedars Sinai Medical Center in Los Angeles, she co-authored several major million-dollar grant requests that were funded, and later served as an investigator on those projects. Dr. Hufnagel later volunteered with the March of Dimes, authoring grants in the field of Nerve Growth Hormone and its role in neural tube defects. She performed pioneering work in women's hormonal health care and first compounded in 1983, and has subsequently created and compounded Natural Cyclic Hormones. Dr. Hufnagel has also worked as an experimental surgeon, perfecting new organ preserving operations. Her current work includes developing a medical treatment for HPV.
Dr. Hufnagel has continued both her medical education and the expansion of her research by obtaining degrees in Alternative and Naturopathic Medicine. As the field of Medicine was drastically in flux, in 2004 she focused her studies in Philosophy, Theology, and Bioethics with a belief that these disciplines would be significant in Research and Development as stem cell and other cellular technologies advanced. Dr. Hufnagel's background offers a unique global outlook in stem cell research and the philosophy of ethical healing.
"I am blessed to be in an area of research and development that has so much life-saving potential. Stem cell work can help us to prevent and cure disease, ameliorate suffering from disease, and unlock the codes of cell growth, metamorphosis, and regeneration. My expertise and position within Stem Cell Assurance will allow me to access the lab where I will be part of the on-going research. We are committed to having the largest and most comprehensive data base on stem cell work available for public access. As a Bioethicist I will be reaching out to the Medical Bioethics community for guidance and support regarding Stem Cell Assurance's future endeavors. It is a time for healing and for deep compassion in the human condition and a time for Science to actively participate in a compassionate way to benefit the World."
About Stem Cell Assurance
- www.stemcellassurance.com Stem Cell Assurance (SCA) is one of the nation's first companies solely established to make available a comprehensive set of Adult Stem Cell services to consumers. SCA will provide genetic profile services and consultations, adult stem cell therapies, adult stem cell research as well as stem cell collection, storage services and cosmetic products. SCA is strategically positioned to enhance the scope of services available to consumers for collection, processing, cryopreservation and storage system. The company specializes in collecting, testing, and banking an individual's own healthy adult stem. These stem cells will serve as the basis for emerging personalized immunological and regenerative therapies. It is very important to note that Stem Cell Assurance is not involved in the use of embryonic stem cells. Stem Cell Assurance works to ensure that the client's adult stem cells will always be available for future use in sustaining life and battling disease. The company is headquartered in Boca Raton, Florida. For more information about Stem Cell Assurance, please visit our website at www.stemcellassurance.com.
----------------------------------------------------------
About Stockwire:
Stockwire is one of the largest communities for Micro Cap Investors. We are the only place on the internet to provide LIVE CHAT ROOMS for dedicated stocks.
We have also pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm.
CONTACT: The Stockwire Group Tel: +1 512 358 8440 e-mail: info@stockwire.com WWW: http://www.stockwire.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
